UNSPSC 51343110: Lamivudine

This classification denotes a reverse transcriptase inhibitor with the molecular formula C8H11N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2T8Q726O95, chemically known as 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1h)-pyrimidinone but generally known as lamivudine, which bears US NIH Compound Identifier 60825. European Medicines Agency schedules Lamivudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08392MIG.

UNSPSC 51343110 Lamivudine is a Commodity code that nominally identifies a single antiretroviral pharmaceutical product, but the recent state and local opportunities posted under this code show a fundamental mismatch: none of the four recent solicitations actually concern lamivudine procurement. Instead, Seminole County, Florida has solicited naloxone and drug deactivation systems; the City of Tampa has solicited emergency medical and first aid supplies for its Fire Department; the Texas Health and Human Services Commission has issued a market-intelligence RFI on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) has solicited generic multi-source pharmaceuticals and OTC products through cooperative purchasing. The code shows little relevant recent activity aligned with its stated pharmaceutical scope, and the opportunities that do appear under it represent a range of unrelated health procurement activities rather than lamivudine supply contracts.

The issuing bodies span state health agencies (Texas HHS Commission), state procurement cooperatives (MMCAP, administered by Minnesota Department of Administration), and local government departments (Seminole County, Florida; City of Tampa Fire Department). Geographic activity is distributed across Texas, Minnesota, Florida, and Oregon (as a MMCAP participant), with no clear concentration in a single state or region. Representative opportunities include MMCAP's RFP for generic pharmaceuticals and OTC products (due March 26, 2026, through cooperative purchasing with authorized wholesalers), the City of Tampa's IFB for medical and first aid supplies at an estimated contract value of $700,000 (due March 13, 2026, with SLBE set-aside and 5 percent discount), and the Texas HHS Commission's RFI on direct-to-manufacturer prescriptions (posted April 3, 2026, as exploratory market research with no award value or binding timeline). The code does not support active demand for lamivudine specifically; firms evaluating this code should verify whether their product or service aligns with the actual procurement patterns state and local agencies are executing.